What Is Cabergoline? Dosage, Half-Life & How to Track It

What cabergoline is and how it works

Dopamine from the hypothalamus normally suppresses prolactin release from pituitary lactotroph cells on an ongoing basis. Cabergoline is an ergot-derived dopamine D2-receptor agonist — it mimics that signal and lowers prolactin directly, rather than acting on the ovary, testis, or thyroid the way most other TRT/AAS ancillaries do.

FDA approval covers hyperprolactinemic disorders (prolactin-secreting pituitary tumors and other causes of elevated prolactin) in both sexes, and that’s the only appropriate use case: lab-confirmed hyperprolactinemia, not a routine or “just in case” addition to a cycle. Off-label, it gets discussed alongside progestin-class 19-nor compounds — nandrolone, trenbolone — on the idea that their progestogenic activity independently raises prolactin and drives gyno-like breast-tissue changes; in reality, gynecomastia is primarily estrogen-mediated, and prolactin is at most a secondary, less-common contributor even with progestin-class compounds. Cabergoline does nothing for the estrogen-driven side of that picture, which is why an aromatase inhibitor — not cabergoline — is the first tool for gyno tied to aromatization; cabergoline’s dopamine-agonist profile and cardiac-valve risk (below) mean it should be reserved for a documented, lab-confirmed elevated prolactin result, not used prophylactically.

Cabergoline was also historically used at much higher doses for Parkinson’s disease before being withdrawn from that indication in a number of countries — the valve-damage findings described below are why.

Dosing & the tablet math

The FDA-labeled starting dose for hyperprolactinemia is 0.25 mg twice weekly, titrated upward in 0.25 mg increments based on prolactin labs, typically not exceeding 1 mg twice weekly in routine use. Off-label AAS use for prolactin management tends to stay at or near the label’s starting point, since the goal is countering one specific progestin’s effect rather than maximal dopaminergic activity.

Dostinex tablets are scored at 0.5 mg, which makes this one of the more forgiving tablet splits among the ancillaries covered here.

The standard starting protocol — 0.25 mg twice weekly — is a half tablet, twice a week, which keeps the arithmetic simple compared to most of the other ancillaries here.

Half-life & what it means for frequency

Cabergoline’s elimination half-life runs roughly 63 to 69 hours — about 2.5 to 3 days — long enough that twice-weekly dosing keeps meaningful drug on board continuously rather than letting prolactin rebound between doses. That long half-life is the whole reason it isn’t dosed daily like most oral ancillaries in this category.

Because of that long half-life, steady state — and the full prolactin-lowering effect — builds gradually over the first several weeks. Judging a dose off the first week’s symptoms undersells what a stable, several-week course typically does.

What to track — and the cardiac-valve caution

Worth monitoring: prolactin directly — the actual signal cabergoline is treating — alongside whether progestin-related symptoms (breast tenderness or discharge, libido, erectile function) track with the lab number.

The FDA label for Dostinex includes a caution about valvular heart disease, based primarily on cases seen at the much higher cumulative doses long used for Parkinson’s disease — which led to cabergoline effectively being withdrawn from that use in many countries. At the low, intermittent doses typical of hyperprolactinemia and off-label AAS use, the absolute risk is far lower, but it’s the reason prescribers may recommend a baseline and periodic echocardiogram for anyone on cabergoline long-term. Other reported effects include nausea, lightheadedness on standing, headache, and — as a dopamine-agonist class effect — rare impulse-control changes.

Frequently asked questions